A certain kind of failure is baked into the E.U.’s institutional DNA.
Big-power muscle flexing helps explain much of the world’s vaccine inequities, but there’s another reason behind insufficient doses: The challenge of making them is unprecedented.
While Washington went into business with the drug companies, Europe was more fiscally conservative and trusted the free market.
The company agreed to deliver the additional doses of its coronavirus vaccine by the end of July, helping address a looming shortage.
The company could provide at least tens of millions of additional doses of a coronavirus vaccine under an agreement that would give it better access to the supplies it needs to expand manufacturing.
Some pharmaceutical companies are scaling back their participation in a federally mandated drug discount program. State attorneys general are demanding that the administration take action.
Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts in Washington to curb drug prices.
The arrangement brings the Trump administration’s investment in coronavirus vaccine projects to more than $8 billion. The head of the federal effort is a former GSK executive.
The French drugmaker is testing two types of vaccines in a bid to catch up to competitors.
Moncef Slaoui, a former pharmaceutical executive, is now overseeing the U.S. initiative to development coronavirus treatments and vaccines. His financial interests and corporate roles have come under scrutiny.
The drug, sarilumab, sold as Kevzara, didn’t show benefits to patients who were hospitalized but not on ventilators. The study will continue with critically ill patients.